CN1974775A - Recombinant plasmid and engineering bacterium containing grass carp interferon gene and their application - Google Patents
Recombinant plasmid and engineering bacterium containing grass carp interferon gene and their application Download PDFInfo
- Publication number
- CN1974775A CN1974775A CN 200610155119 CN200610155119A CN1974775A CN 1974775 A CN1974775 A CN 1974775A CN 200610155119 CN200610155119 CN 200610155119 CN 200610155119 A CN200610155119 A CN 200610155119A CN 1974775 A CN1974775 A CN 1974775A
- Authority
- CN
- China
- Prior art keywords
- interferon
- group
- grass carp
- rabbit
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010050904 Interferons Proteins 0.000 title claims abstract description 103
- 241000252230 Ctenopharyngodon idella Species 0.000 title claims abstract description 35
- 241000894006 Bacteria Species 0.000 title claims abstract description 31
- 239000013612 plasmid Substances 0.000 title claims abstract description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 56
- 241001465754 Metazoa Species 0.000 claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 239000002773 nucleotide Substances 0.000 claims abstract description 6
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims abstract description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 abstract description 44
- 241000700605 Viruses Species 0.000 abstract description 6
- 102000014150 Interferons Human genes 0.000 description 88
- 229940079322 interferon Drugs 0.000 description 71
- 238000012360 testing method Methods 0.000 description 60
- 241000283973 Oryctolagus cuniculus Species 0.000 description 53
- 201000010099 disease Diseases 0.000 description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 39
- 235000019688 fish Nutrition 0.000 description 30
- 241000251468 Actinopterygii Species 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 22
- 238000000034 method Methods 0.000 description 22
- 241000238557 Decapoda Species 0.000 description 20
- 238000011161 development Methods 0.000 description 18
- 230000018109 developmental process Effects 0.000 description 18
- 210000005259 peripheral blood Anatomy 0.000 description 17
- 239000011886 peripheral blood Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 14
- 208000026278 immune system disease Diseases 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 230000001939 inductive effect Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000034994 death Effects 0.000 description 10
- 239000002516 radical scavenger Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000238553 Litopenaeus vannamei Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 101100440919 Escherichia phage 186 CP80 gene Proteins 0.000 description 5
- 239000003674 animal food additive Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 241000269799 Perca fluviatilis Species 0.000 description 4
- 241000696962 White spot syndrome virus Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000031295 Animal disease Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 238000009360 aquaculture Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 241000252212 Danio rerio Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003905 agrochemical Substances 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000012262 fermentative production Methods 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 229940088592 immunologic factor Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004719 natural immunity Effects 0.000 description 2
- 230000006855 networking Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 241001139305 Channa asiatica Species 0.000 description 1
- 241000252210 Cyprinidae Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 241000277263 Salmo Species 0.000 description 1
- 241001441722 Takifugu rubripes Species 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
- 101150099105 alien gene Proteins 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000021393 food security Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229950004152 insulin human Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 101150008049 mx gene Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention discloses one kind of recombinant plasmid containing grass carp interferon gene with the nucleotide sequence as shown in SEQ ID No. 1. The present invention also discloses engineering bacterium INVSC1-pYES2-IFN as one kind of Saccharomyces cerevisiae in the preservation number of CGMCC1847. The engineering bacterium is used for aquatic animals to resist viruses. The present invention also discloses the application of protein coded by the recombinant plasmid containing grass carp interferon gene with the nucleotide sequence as shown in SEQ ID No. 1 for aquatic animals to resist viruses.
Description
Technical field
The present invention relates to aquatic living things technology and aquiculture disease Prevention Technique field.Be particularly related to a kind of Protocols in Molecular Biology that utilizes, clone's grass carp interferon gene, structure contains the expression of recombinant yeast plasmid of this gene, and in yeast saccharomyces cerevisiae, obtain to efficiently express, utilize the Yeast engineering bacteria of expressing Interferon, rabbit, directly be developed into the disease-resistant feed additive, be applied to disease control of aquatic animal.
Background technology
Along with the fast development of fish production, aquatic animal disease becomes increasingly conspicuous, and has become the global problem that current serious influences the healthy Sustainable development of culture fishery, and is especially outstanding in China.In recent years, the due to illness harmful culture fishery direct economic loss that causes of China is annual to surpass 10,000,000,000 yuan, and soaring year by year.But for a long time, lack effective pest control method always; Various microbiotic, sterilant abuse cause breeding environment and fishery products severe contamination, and aquatic food safety is subjected to serious threat, and the resistance of microbiotic generation has simultaneously been aggravated the generation of aquatic animal disease again, forms vicious cycle.Promulgation along with China joined WTO and food safety method, standard to environment and food safety is more and more higher, current large quantities of microbiotic is forbidden by explicit order, disease control of aquatic animal has faced the predicament that no medicine can be executed, therefore develop natural, safe, the disease control of aquatic animal medicine is extremely urgent efficiently, it is to supporting China's water industry healthy and sustainable development, guarantee food security in China, improve national health quality, lead the innovation of China's fishery economic development and aquatic science all extremely important and very urgent, have great economic society meaning.
The development and use of the important immune disease-resistance factor of aquatic animal are the effective ways that fundamentally solves disease control of aquatic animal, ensures aquatic food safety.Yet because long-term next relatively weaker to the research of the aquatic animal immune disease-resistance factor both at home and abroad, particularly the crucial disease-resistant factor of isolation identification is very limited, and therefore, the Application and Development research in relevant this field also almost is blank.
(Interferon is the non-specific immunity factor of most critical in the body natural immunity IFN) to Interferon, rabbit, is that a kind of that body is subjected to that the secretion of infection such as virus back produces has antiviral and glycoprotein immunoregulatory activity.Yet, its research and development is used mainly be seen in the clinical and part higher animal of physianthropy at present, as livestock and poultry.Research as vertebrate fish interferon such as low is also less, shows also few to the understanding of its biological property and immunologic function, also almost is blank to its Application and Development research in disease control of aquatic animal particularly.Because have bigger ethnic specificity difference between human (comprising higher animal) and fish, existing human interferon preparation is not suitable for aquatic animals such as fish; Be in particular in that human interferon is active low in fish, particularly human interferon is applied to aquatic animal potential food safety hazard, and therefore, the Interferon, rabbit of developing aquatic animal self is a urgent subject.Requiring different with the development of physianthropy Interferon, rabbit is that aquatic animal requires easy to use, with low cost with Interferon, rabbit, actual application value is so just arranged.Medically, can also can prepare recombinant interferon from human leukocyte separating natural Interferon, rabbit by genetically engineered, but because modes such as injection injection are adopted in the use of human interferon, the purity requirement height, cost will improve greatly like this; And the singularity that aquatic products is lived owing to the aquatic animal water body with Interferon, rabbit, should not adopt individual one by one injection injection system, adopt fodder additives to throw something and feed to be desirable and approach easily, simultaneously in order to reduce cost, the natural extract method generally is difficult to realize, therefore adopting recombination and expression techniques is suitable way comparatively.
Summary of the invention
Technical problem to be solved by this invention provides a kind of recombinant plasmid that contains grass carp interferon gene, and contain this plasmid and can efficiently express the proteic saccharomyces cerevisiae engineered yeast of GcIFN, this project bacterium and GcIFN albumen can be used for the antiviral and raising immune disease-resistance ability of aquatic animal.
In order to solve the problems of the technologies described above, the invention provides a kind of recombinant plasmid that contains grass carp interferon gene, this gene has the nucleotide sequence shown in the SEQ ID NO.1.
The present invention also provides a kind of engineering bacteria, this bacterial strain INVSC1-pYES2-IFN is S. cervisiae Saccharomyces cerevisiae, depositary institution: China Committee for Culture Collection of Microorganisms common micro-organisms center, preservation day: on October 19th, 2006, preserving number: CGMCC1847.
The present invention also provides the application of above-mentioned engineering bacteria in aquatic animal is antiviral.
The present invention also provides the application of a kind of protein in aquatic animal is antiviral, and this protein is that to have a grass carp interferon gene of nucleotide sequence shown in the SEQ ID NO.1 coded.
The inventor system at home and abroad of taking the lead in has carried out the research of GcIFN, successively from grass carp serum and white corpuscle separation and purification ifn protein, systematic study its histocyte source, induce and produce rule, physico-chemical property and immunoloregulation function; And cloned its gene; realized GcIFN albumen efficiently expressing in yeast saccharomyces cerevisiae (expression amount reaches 30%); the GcIFN of having measured yeast expression has the biologic activity identical with natural interferon; and utilize the Yeast engineering bacteria of express interferon in high efficiency; by ultrasonication and air stream drying; be developed into the yeast powder disease-resistant feed additive that contains GcIFN; through disease control of aquatic animal application tests such as fishes and shrimps; obtain good result; showing that GcIFN has generally is applicable to the provide protection of aquatic animal immune disease-resistance; have significant application value, the development and use to this disease-resistant factor at home and abroad still belong to the first time.
The inventor has also taken the lead in the grass carp isolation identification disease-resistant key factor Interferon, rabbit of fish immunity, by systematic study to its biological property and function, the proof fish interferon has the antiviral activity of wide spectrum, simultaneously fish scavenger cell and lymphocyte etc. had tangible activation, function with remarkable adjusting and enhancing body immune level is the aquatic animal disease-resistant factor with important development and application values.
In existing technical field, developed multiple expression system at present, comprised protokaryon and eukaryotic expression system, as bacterium, yeast, animal and plant cells etc.; By comparative analysis, we find that intestinal bacteria and the pichia yeast expression system used always have certain toxicity to aquatic animals such as fish, are not suitable for directly as the disease-resistant feed Application and Development, and the animal and plant cells expression system then needs large scale culturing, the cost height.We adopt the yeast saccharomyces cerevisiae system that GcIFN is developed for this reason, to guarantee its safety non-toxic, because yeast saccharomyces cerevisiae itself can be used as feed, are suitable for throwing something and feeding simultaneously, and the fermentative production cost is low, is the idealized system of aquatic animal active factor Application and Development.
Yeast saccharomyces cerevisiae is mainly used in brewing industry at present, also can be used as yeast feed in addition and is used for fodder industry.Yeast feed is meant and utilizes saccharomycetic metabolism and breeding thalline, by fermentation the high-quality feed of safe, pollution-free, the noresidue that contains thalline and yeast cell meta-bolites made from technology such as drying.Utilize the yeast saccharomyces cerevisiae expression alien gene to have translation post-treatment ability, the exogenous protein of results has to a certain degree folding processing and glycosylation modified, be particularly suitable for expressing eukaryotic gene, in drug developments such as hepatitis B vaccine, insulin human, Filgrastim, people's blood vessel statin, used at present, but the application in the fish drug development seldom, utilize it to express Interferon, rabbit, and directly still belong to the first time as the Application and Development of disease-resistant feed.In addition, yeast saccharomyces cerevisiae is applied to produce advantages such as to have a growth and breeding rapid, and technology is simple, can tolerate higher hydrostatic pressure, can scale operation, effectively reduce production costs, and have very strong practicality.
The application in aquatic animal is antiviral of engineering bacteria of the present invention and protein, being embodied in initiative becomes the disease-resistant preparation of a kind of aquatic animal Interferon, rabbit, and is developed into the application of yeast feed additive form; Purpose is to develop China's economic fish natural immunity disease-resistant factor; protection China fish important gene resource; substitute the harmful medicine of abusing in the present fish production of microbiotic, agrochemical; ensure food safety, solving the viral disease of aquatic animal does not simultaneously still have effectively this global problem of control medicine at present.The fish interferon preparation is with the application of fodder additives form, can overcome in the past the medical science interferon formulation and cost an arm and a leg and inject give defectives such as medicine is difficult to apply in aquaculture of aquatic animal.
Aquatic animal immune disease-resistance preparation mentioned above, for containing the expressed GcIFN albumen of grass carp interferon gene expression plasmid Yeast engineering bacteria, or the Yeast engineering bacteria bacterium powder of expression GcIFN, the ratio of the shared yeast total protein of interferon protein is 20%～30%.Therefore this aquatic animal immune disease-resistance preparation has antiviral function and immunomodulatory biological function, in grass carp ZC7901 kiss terminal cell and the strain of CP80 embryonic cell, has inhibition grass carp hemorrhage virus (GCHV) (GCHV) activity, its titre (Log
2CPEI
50/ 0.1ml) reach more than 11.29 ± 0.18; Grass carp dorsal fin subcutaneous injection in one age interferon protein (10 μ g/ tail) is after 12 hours, artificial challenge GCHV (500TCID
50)/tail, (Relative Percent Survival RPS) can reach 59.42% to the premunition protection ratio; One feed (10mg GcIFN/Kg feed) that grass carp was fed and contained Interferon, rabbit age was fed for 1 week artificial challenge GCHV (500TCID continuously
50)/tail, the premunition protection ratio can reach 29.58%; The yeast powder of expressing GcIFN is added into mixed bait (Interferon, rabbit content is 10mg GcIFN/Kg in the bait), feed Penaeus vannamei and Chinese prawn, every day 2 times, fed continuously 7 days, artificial challenge's white spot syndrome virus (WSSV), the premunition protection ratio reaches 11.60% and 10.40% respectively; The scavenger cell of handling through Interferon, rabbit has significant enhancing and engulfs germicidal action to saccharomycetic, Interferon, rabbit also has tangible promotion propagation transformation to peripheral blood and head-kidney T, bone-marrow-derived lymphocyte simultaneously, disease-resistant test to cultured fishes shows, use contains the experimental group grass carp and the perch of Interferon, rabbit feed, surviving rate all obviously improves, and immune protective rate reaches 62.39% and 48.61% respectively; Disease-resistant test to shrimps in culture shows, uses the experimental group Penaeus vannamei and the Chinese prawn that contain the Interferon, rabbit feed, and surviving rate obviously improves, and immune protective rate reaches 30.80% and 20.99% respectively, shows that IFN can improve the immune disease-resistance ability of fish and shrimp.
The disease-resistant preparation of aquatic animal Interferon, rabbit provided by the present invention, its advantage mainly shows: the Interferon, rabbit that express with yeast saccharomyces cerevisiae (1) is a kind of immune disease-resistance factor that derives from animal itself, not only has biologic activity, and safety non-toxic, cheap; (2) the bacterium powder of saccharomyces cerevisiae engineered yeast preparation can be fit to throw something and feed directly as feed, has overcome the difficulty that aquatic animal can't drug administration by injection; (3) interferon protein not only has antivirus action, also has immunoloregulation function, can strengthen the resistance against diseases of aquatic animal self; (4) this preparation has the resistant effect of wide spectrum, also can be used for the disease control of multiple aquatic animal such as perch, prawn except that grass carp.
Beneficial effect of the present invention, specific as follows:
The present invention has taken the lead at home and abroad isolation identification GcIFN immune factor, by systematic study to this factor biological property and function, confirm that Interferon, rabbit is the crucial immune disease-resistance factors of fish, on this basis, by clone's grass carp interferon gene and structure GcIFN efficient expression plasmid, realized this factor efficiently expressing in yeast saccharomyces cerevisiae, utilize the Yeast engineering bacteria of expressing Interferon, rabbit, through suitable art breading, be developed into the disease-resistant feed additive, in disease control of aquatic animal such as fish and shrimps, carry out disease-resistant test, obtain good result.
Fish interferon is as a kind of important immune disease-resistance factor, has great development and application values, it is as safe, efficient, the natural disease control of aquatic animal medicine of a kind of alternative microbiotic and agricultural chemicals, can open up new way for the disease control of perplexing China's fishery development for a long time, to promoting the healthy Sustainable development of China's water industry, guarantee food safety, improve national health quality, lead the innovation of China's fishery economic development and aquatic science to have important economical, societal benefits.Achievement in research has the most important theories meaning to molecular composition and mechanism of action, immune factor molecule origin and the evolution rule that discloses the fish immunity system simultaneously.
Description of drawings
Fig. 1 is the structure of the recombinant expression plasmid IFN-pYES2 of an embodiment of the present invention.
Fig. 2 is that the bacterium colony PCR of the goal gene of an embodiment of the present invention identifies figure.
Fig. 3 is that the recombinant plasmid I FN-pYES2 of an embodiment of the present invention identifies figure through Hind III and Xho I double digestion, and it is identical with the expection size that the disconnected size of enzyme section is about 550bp.
Fig. 4 is the SDS-PAGE analysis chart of the pYES2-IFN/INVSC1 abduction delivering of an embodiment of the present invention; The arrow indication is a target protein among Fig. 4, and its molecular weight is 38000Da; The 3rd classifies empty carrier as, and the 4th, 5,6 row are respectively the expression of the interferon protein of inducing 14,38,60 hours, and expression amount is the highest when 14h induces.
Fig. 5 is time gradient and the concentration gradient effect synoptic diagram that the GcIFN of an embodiment of the present invention induces the Mx gene, and the result shows that the amount of inducing of Mx increases along with the increase of the amount of the IFN concentrated solution that adds; And adding under the prerequisite of the amount of inducing equally, behind the highest 24 hours of inducing peak value to appear to add behind the inductor, to beginning to go down in 36 hours.
Embodiment
Below in conjunction with accompanying drawing and embodiment the present invention is described in further detail:
Embodiment 1, grass carp interferon gene clone
From grass carp dorsal fin subcutaneous injection 0.5ml poly I:C (available from the pharmaceutical factory, Tianjin), 26 ℃ of water temperatures are injected once after inducing 12hr again, get after 12 hours about head-kidney 10 grams, and (Gibco BRL USA) extracts total RNA, and the extracting method by specification carries out with TRizol.(TaKaRa USA) carries out reverse transcription and pcr amplification to use reverse transcription test kit RNA PCR kit (AMV) Ver3.0 then.Primer sequence is as shown in table 1.
(use PCR product purification test kit DNA Gel Extraction Kit, V-gene) insert T carrier (TA clone test kit is given birth to the worker available from Shanghai) behind the amplified production purifying.Operation steps all to specifications shown in.Connect product transformed into escherichia coli TOP10, the evaluation of checking order of screening positive recombinant.Conversion and authentication method carry out according to " molecular cloning experiment guide ".Sequences Design 5 ' the RACE and 3 ' the RACE primer (its sequence is as shown in table 1) that obtain according to evaluation, use TaKaRa 5 '-Full RACE Core Set and TaKaRa 3 '-described to specifications step of Full RACE Core Set to carry out 5 ' RACE and 3 ' RACE amplification, carry out the splicing-in of sequence at last, obtain the cDNA sequence of long 1191 bases.Analyze the long 543bp of open reading frame ORF as can be known with NCBI ORFFinder, 180 amino acid of encoding.The long 34bp of all the other 5 ' UTR, the long 614bp of 3 ' UTR.
Table 1. grass carp interferon gene pcr amplification the primer (5 '-3 ')
| IFN ORF amplimer | IFN-F1 IFN-R1 | AAGGAAATGGGTGGAAAATAT TTGCGATGATGTCCATCCTC |
| IFN 3 ' RACE primer | IFN-3-F3 3’Adaptor primer | ACCTTCAGAGGATGGACATGAT CTGATCTAGAGGTACCGGATCC |
| IFN 5 ' RACE primer | RT A1 A2 S1 S2 | (P)-GATGACTGCCTG AGGTGGAAAATATCCTGAGGG AAGGTGTCATTTCCAGGAGC GAGCCATTCGCAAGCAGAGC CGCAAGCAGAGCATTGACCC |
Analyze the cDNA sequence of gained among the embodiment 1 with NCBI ORF Finder, the long 543bp of open reading frame ORF as can be known, 180 amino acid of encoding.The long 34bp of all the other 5 ' UTR, the long 614bp of 3 ' UTR; Carry out the analysis of potential function site and carry out the analysis of signal attitude with PROSITE database with signal peptide analysis software SignalPprogram (version 3.0), the conclusion that draws is that its albumen iso-electric point is 9.73, and this gene have one long be 22 each amino acid whose signal peptide, indicating that its mature peptide is 159 amino acid; Carry out the site with Prosite and analyze, find that this gene has 2 N-terminal, 14 acidylate site: GqcsAC and GTkvSF simultaneously; 2 protein kinase ii phosphorylation sites: SacE ShkE; N-terminal glycosylation site a: NESL; Protein kinase C phosphorylation site a: ShK; Two karyomit(e)s are examined leader sequence: Kkinrhfkilkknlkkk and Kkeysaqaweqirravk; With software ClastalW gene order of the present invention and other eight kinds of biologies are comprised that the IFN homologous gene sequence of people, mouse, atlantic salmon, chicken, zebra fish, crucian, Fugurubripes and catfish carries out the multisequencing comparison, the result shows that the homogenic aminoacid sequence of IFN homology in the species of different fish is higher.Wherein, grass carp and zebra fish and crucian are all Cyprinidae, and there is very high homology in their aminoacid sequence, reaches more than 90%.
The structure of embodiment 3, GcIFN expression plasmid
According to the interferon gene sequences Design expression vector establishment primer that embodiment 1 obtains, sequence is as follows:
Upstream primer is initial from GcIFN ATG, and 5 ' end contains Hind III restriction enzyme site and Kozak sequence A CC
gc-IFN-F3：5’-CCC AAG CTT GGG ACC ATG GAA ACT CAA ATGTGG-3’
Downstream primer autotermination cipher word TAA begins, and 5 ' end adds Xho I restriction enzyme site
gc-IFN-R3：5’-GGCGAGCTCGCCTTATCGTCTGTTGGCAATGC-3’
Carry out pcr amplification according to method among the embodiment 1, amplified production is carried out double digestion with Hind III and Xho I (TAKARA company), be inserted among the expression vector pYES2, transformed into escherichia coli TOP10, according to the alkaline lysis method of extracting recombinant expression plasmid in " molecular cloning experiment guide ", the evaluation of checking order, the sequencing result proof obtains the correct recombinant expression plasmid of direction of insertion, contain complete GcIFN gene, the about 560bp of length comprises that length is the signal peptide of 22 aa.The gene 5 ' end has Hind III restriction enzyme site, and 3 ' end contains Xho I restriction enzyme site.The construction of recombinant plasmid scheme as shown in Figure 1.
Saccharomyces cerevisiae engineered yeast structure, screening and the abduction delivering thereof of embodiment 4, expression GcIFN
4.1, recombinant plasmid electricity transformed yeast cell
The a small amount of plasmid of alkaline lysis extracting, method is referring to " molecular cloning experiment guide ".Preparation yeast competent cell, method is as follows: a mono-clonal INVSC1 is in the 2mlYPD liquid nutrient medium in the picking YPD substratum, and 30 ℃, 250～300rpm shaking culture is spent the night; The SC suspension that takes a morsel is coated with the SC flat board, identifies phenotype; Get 200ul and be seeded to the triangle that 100ml contains the YPD substratum and shake in the bottle, 30 ℃, 250～300rpm shaking culture spend the night to OD600 be 1.3～1.5; Cell ice bath 15min stops growth; 4 ℃ of 3000rpm5min centrifugal collecting cells, resuspended with the sterilized water of 100ml precooling; 4 ℃ of 3000rpm 5min centrifugal collecting cells, resuspended with the sterilized water of 50ml precooling; 4 ℃ of 3000rpm 5min centrifugal collecting cells, resuspended with the 1M sorbyl alcohol of 4ml precooling; 4 ℃ of 2000rpm 5min centrifugal collecting cells, resuspended with the 1M sorbyl alcohol of 100ul precooling, final volume is about 200～300ul, presses the packing of 40ul/ pipe, 4 ℃, preserves a week; After obtaining the yeast competent cell, change recombinant plasmid over to yeast saccharomyces cerevisiae with the electricimpulse method for transformation, method is as follows: with 40ul yeast suspension and the electroporation pipe (0.2cm) that is mixed in precooling less than the 5ul plasmid DNA, at the bottom of the jog pipe, to guarantee sample and aluminum pipe contact both sides, ice bath 5min; Pulse parameter: V=1.5kV, 25uF, 200Ohms, 4-5ms; Add the 1M sorbyl alcohol of 1ml precooling after electricity transforms at once, be transferred to sterile eppendorf tubes with aseptic transfer pipet; Select to cultivate every 200ul coating one flat plate in the coating SC-U substratum; Flat board as for 30 ℃ of cultivations, is occurred until single bacterium colony.
4.2, the screening positive transformant
(sky is the epoch, DP112) to extract yeast plasmid DNA with the little extraction reagent kit of yeast plasmid.With the yeast plasmid that obtains transformed into escherichia coli TOP10 again, alkaline lysis extracting plasmid (method is referring to " molecular cloning experiment guide ") is identified positive transformant with methods such as PCR and Hind III, Xho I double digestions, and qualification result is shown in accompanying drawing 2,3.
4.3, the abduction delivering of recombinant interferon
Choose single bacterium colony recon and contain in the 15ml SC-U substratum of 2% raffinose, 30 ℃ of shaking culture are spent the night; Get overnight culture and survey OD
600Be worth, calculate the quantity of the overnight culture of required adding in the 50ml inducing culture thus, the inducing culture initial OD values need reach 0.4; Measure overnight culture, 4 ℃, 1, the centrifugal 5min of 500g, collecting cell according to what calculate gained; With 1～2ml inducing culture re-suspended cell, inoculation and 50ml inducing culture, 30 ℃ of shaking culture; Collecting cell in 0,2,4,6,8,10,12 hour.Each period sampling 5ml surveys OD respectively
600Value; 4 ℃, the centrifugal 5min of 1500g, collecting cell; Abandon supernatant, with 500ul aqua sterilisa re-suspended cell; With cell transfer to 1.5ml eppendorf pipe, high speed centrifugation 30sec; Abandon supernatant ,-80 ℃ of preservations.
4.4, the evaluation expressed of interferon protein
With 500ul lysate (BioDev-Tech, DB001-12) re-suspended cell, 4 ℃ of centrifugal 5min of 1500g, collecting cell; Abandon supernatant, use the lysate re-suspended cell, OD
600Value is transferred to 50-100, adds isopyknic granulated glass sphere (Sigma G-8772) vibration 30sec, and ice bath 30sec repeats 4 times the cracking cell, gets part microscopy observation of cell crushing effect then; High speed centrifugation 10min; Drawing supernatant liquor is transferred in another clean centrifuge tube; Add SDS-PAGE sample buffer to final concentration and be 1 *, boil 5min; Get 20ul lysate application of sample, carry out the SDS-PAGE electrophoresis,, identify the band of expressing protein through coomassie brilliant blue staining.The result as shown in Figure 4.
The biological function of embodiment 5, interferon protein is identified
5.1 the extraction of interferon protein
Adopt non-denatured gradient PAGE (6%～20%) electrophoretic separation interferon protein (method is referring to " molecular cloning experiment guide "), electrode solution is 0.025mol/L Tris-0.192mol/Lgly (pH8.3), behind the 100V electrophoresis 6 hours, cut the dyeing of Partial Protein band, cut the gel band that contains ifn protein according to coloration result then, pack in the dialysis tubing of handling, add appropriate amount of buffer solution, put into the electrophoresis elution groove, 25mA4 ℃ of low temperature electrophoresis 2-3 hour, collect interferon protein liquid, frost drying concentrates, and uses high performance liquid chromatography (HPLC) purifying again, with Tianjin, island Shim-Pack DIOL-150 gel separation post (column length 25cm, diameter 0.79cm), elutriant is for containing 0.2mol/L Na
2SO
410mmol/L PB damping fluid (pH7.2), flow velocity 1mL/min detects wavelength 280nm, the Interferon, rabbit sample concentrates through frost drying, is stored in-20 ℃, is used for mensuration such as active and function.Suppress (CPEI with the half cytopathy before using
50) method records it and active be 105U/ml, is mixed with 5000U/ml, 500U/ml, 250U/ml, 50U/ml and 5U/ml with L-15 or TC-199 nutrient solution during use.
5.2 inducing the Mx expressive function identifies
Mx albumen is the important factor of Interferon, rabbit signal path downstream performance antivirus action, and inducing the proteic expression of Mx is the important indicator of identifying the Interferon, rabbit function.The interferon protein that extracts is joined in the grass carp ZC7901 cell, carry RNA (method is with embodiment 1) respectively at sampling in 12 hours, 24 hours, 36 hours, with RT-PCR method identification of M x expression of gene (accompanying drawing 5).
Primer sequence is as follows:
Upstream primer (Mx-F): 5 '-ACATGTCTCCAAGCACTTCTT-3 '
Downstream primer (Mx-R): 5 '-TATTGACTGTTCTGACCACCG-3
5.3 the antiviral activity of interferon protein is measured
5.3.1 the antiviral activity in the fish cell level is measured
Adopt the half cytopathy to suppress (CPEI
50) method carries out, grass carp ZC7901 and the strain of CP80 embryonic cell after the dilution interferon protein effect of difference, add 100TCID respectively
50Grass carp hemorrhage virus (GCHV) GCHV and grass carp picornavirus (GCPV) are attacked, and are an interferon activity unit can suppress 50% cytopathic high dilution, use Log
2CPEI
50/ 0.1ml represents.The result is as shown in table 2.
The determination of activity of table 2.GcIFN in ZC7901 and CP80 cell
| Virus | Cell * | The Interferon, rabbit titre ** | ||
| The recombinant interferon test group | The natural interferon control group | The blank group | ||
| GCHV | ZC7901 | 11.36±0.32 | 11.45±0.55 | 0 |
| GCHV | CP80 | 11.29±0.18 | 11.87±0.38 | 0 |
| GCPV | ZC7901 | 11.15±0.66 | 11.06±0.12 | 0 |
| GCPV | CP80 | 11.40±0.17 | 11.79±0.58 | 0 |
*Use 100TCID
50GCHV (TCID
50=10
5.8/ 0.1ml) and GCPV (TCID
50=10
5.2/ 0.1ml) infect
*IFN titre: Log
2CPEI
50/ 0.1ml, (X ± SD), n=5
5.3.2 the antiviral activity of fish body level is measured
5.3.2.1 give the disease-resistant test of Interferon, rabbit by injecting pathway
One grass carp in age (10～12cm is long), dorsal fin subcutaneous injection IFN albumen, 0.1ml (10 μ g)/tail, artificial challenge GCHV (500TCID after 12 hours
50)/tail, 28 ℃ of water temperatures raised for 2 weeks, the statistics death rate of the onset, calculating premunition protection ratio (Relative Percent Survival, RPS), RPS=(1-immune group mortality ratio/control group mortality ratio) * 100%, control group is injected blank PBS liquid.The result is as shown in table 3, and IFN has tangible disease resisting effect by injection system, and the surviving rate of its injection group improves 47.68% than control group, and immune protective rate reaches 59.42%.
The disease-resistant test-results of table 3. fish body injection GcIFN
| Group | Fish (tail) | Death toll (tail) | Survival number (tail) | Surviving rate (%) | Average survival (%) | Surviving rate improves (%) | RPS (％) |
| Test 1 group | 30 | 10 | 20 | 66.66 | 67.45 | 47.68 | 59.42 |
| | 35 | 12 | 23 | 65.71 | |||
| Test 3 groups | 30 | 9 | 21 | 70.00 | |||
| Contrast 1 group | 30 | 25 | 5 | 16.66 | 19.77 | ||
| | 30 | 22 | 8 | 26.66 | |||
| Contrast 3 groups | 25 | 21 | 4 | 16.00 |
5.3.2.2 give the disease-resistant test of Interferon, rabbit by the approach of feeding
One feed (the per kilogram feed adds GcIFN engineering bacteria powder 33mg, the expression amount 30% of interferon protein in yeast, i.e. 10mg GcIFN/Kg feed) that grass carp was fed and contained Interferon, rabbit age was fed for 1 week artificial challenge GCHV 0.1ml (500TCID continuously
50)/tail, 28 ℃ of water temperatures raised for 2 weeks, and the statistics death rate of the onset calculates the premunition protection ratio.Control group fed does not contain the normal feed of Interferon, rabbit.The result is as shown in table 4, by the mode of feeding, tangible disease resisting effect is arranged also, and the surviving rate of its test group improves 23.92% than control group, and immune protective rate reaches 29.58%.
Table 4. fish body is fed and is contained the disease-resistant test-results of GcIFN feed
| Group | Fish number (tail) | Death toll (tail) | Survival number (tail) | Surviving rate (%) | Average survival (%) | Surviving rate improves (%) | RPS (％) |
| Test 1 group | 40 | 23 | 17 | 42.50 | 43.14 | ||
| | 40 | 24 | 16 | 40.00 | |||
| Test 3 groups | 52 | 27 | 25 | 48.07 | |||
| Test 4 groups | 50 | 29 | 21 | 42.00 |
| Contrast 1 group | 30 | 25 | 5 | 16.66 | 19.21 | ||
| | 30 | 24 | 6 | 20.00 | |||
| Contrast 3 groups | 28 | 22 | 6 | 21.42 |
5.3.3 the shrimps antiviral activity of GcIFN test
Adopt the bait addition manner to test, the yeast powder of expressing GcIFN is added into mixed bait, Interferon, rabbit content is 10mg GcIFN/Kg bait in the bait, and the experiment prawn is adopted Chinese prawn and Penaeus vannamei respectively.Experiment divides 5 groups, and every group 100 tail, control group fed do not contain the normal bait of Interferon, rabbit.Feed every day 2 times, fed continuously 7 days, then artificial challenge's white spot syndrome virus (WSSV).Virus infection adopts the method for the poison bait of throwing something and feeding to carry out, and every day, each was was once thrown something and fed 3 days continuously sooner or later, kept 20～25 ℃ of water temperatures, and statistics death rate of the onset after 1 week calculates premunition protection ratio RPS.The result is as shown in table 5, and grass carp IFN has tangible immune disease-resistance effect to two kinds of shrimps, and the immune protective rate of test group reaches 11.60% and 10.40% respectively.
Table 5. GcIFN is to the disease-resistant test of Penaeus vannamei and Chinese prawn
| Group death toll (tail) | Penaeus vannamei (control group) | Penaeus vannamei (test group) | Chinese prawn (control group) | Chinese prawn (test group) |
| Test 1 group | 100 | 90 | 100 | 92 |
| | 100 | 86 | 100 | 89 |
| Test 3 groups | 100 | 89 | 100 | 88 |
| Test 4 groups | 100 | 92 | 100 | 90 |
| Test 5 groups | 100 | 85 | 100 | 89 |
| On average | 100 | 88.40 | 100 | 89.60 |
| RPS(％) | 11.60 | 10.40 |
5.4 the immunoloregulation function of Interferon, rabbit is measured
5.4.1 GcIFN is to the immunoregulation effect of scavenger cell
Adopt the 34%-51%Percoll density gradient centrifugation to separate grass carp head-kidney scavenger cell, in L-15 nutrient solution (containing 5%FCS, 10% penicillin/streptomycin), cultivated 12 hours for 27 ℃, PBS cleans, expect blue sampling dyeing for 2%, when amount of viable cell reaches 98% when above, add 500U/ml Interferon, rabbit effect 24 hours, adding final concentration respectively after PBS cleans 3 times is 10
5Individual/ml, 10
4Individual/ml, 10
3Individual/ml and 10
2Individual/the ml yeast, cultivated 0,3 and 5 hour for 27 ℃, measure saccharomycetic MTT color reaction and scavenger cell bactericidal index (KI), establish simultaneously and do not add the Interferon, rabbit treatment group in contrast.
The result shows that the scavenger cell after Interferon, rabbit activates needs a suitable action time to saccharomycetic engulfing with killing action, and also needing simultaneously has a proper proportion between scavenger cell and yeast.In 105 left and right sides scavenger cells, insert 10
5Or 10
4Individual yeast, and after acting on 5 hours, remaining viable yeast amount with compare obvious minimizing without Interferon, rabbit activated scavenger cell, the sterilizing power utmost point strengthens (seeing Table 6) significantly.
Table 6. Interferon, rabbit is to the regulating effect of grass carp scavenger cell sterilizing power
| The experiment group | Saccharomycetic MTT color reaction (OD570nm) and KI value | |||
| Yeast number (No.of yeast) | ||||
| 10 2 | 10 3 | 10 4 | 10 5 | |
| Engulf the 0h contrast | 0.30±0.01 | 0.36±0.02 | 0.65±0.01 | 0.76±0.01 |
| Engulf 3h, add GcIFN | 0.24±0.02 (0.80±0.01) | 0.31±0.01 (0.86±.0.01) | 0.58±0.03 (0.89±0.02) | 0.64±0.02 (0.84±0.02) |
| Engulf 3h, do not add GcIFN | 0.23±0.02 (0.77±0.01) | 0.34±0.001 (0.94±0.01) | 0.55±0.02 (0.85±0.02) | 0.69±0.04 (0.91±0.03) |
| Engulf 5h and add GcIFN | 0.18±0.01 (0.60±0.01) | 0.22±0.03 (0.61±0.03) | 0.50±0.02 (0.77±0.01) | 0.58±0.01 (0.76±0.01) |
| Engulf 5h, do not add GcIFN | 0.21±0.01 (0.70±0.01) | 0.24±0.005 (0.67±0.005) | 0.55±0.005 (0.85±0.005) | 0.66±0.005 (0.87±0.01) |
P＜0.01 t check, with the control group that does not add GcIFN relatively, in the bracket for the KI value (X ± SE, n=5)
5.4.2 the regulating effect that Interferon, rabbit transforms T, bone-marrow-derived lymphocyte
5.4.2.1 Interferon, rabbit is to the lymphocytic regulating effect of T of mitogen PHA and ConA conversion
Adopt the ficoll density gradient centrifugation to separate peripheral blood and head-kidney white corpuscle, adding final concentration respectively after Interferon, rabbit is handled is 0.64mg/ml PHA and 25mg/ml ConA, cultivate after 24 hours for 27 ℃ and carry out the 3H-TdR mark (than degree 20Ci/mmol, concentration 1mCi/ml, mark final concentration 2 μ Ci/ml) labeled cell is used the per minute umber of pulse (CPM) of TRI-CARB 2050 CA type liquid glimmer instrument working samples then.
The result shows that Interferon, rabbit is to PHA and ConA transforms peripheral blood and head-kidney T lymphocyte has tangible regulating effect, shows when lower concentration is handled that significant promoter action is arranged, and high density then has significant inhibitory effect when handling.Interferon, rabbit promotes PHA and the lymphocytic dosage of ConA conversion T to be respectively 500U/ml and 250～500U/ml, and suppressing the LT dosage of T is 5000U/ml, and promotion or the time of suppressing to transform are more than 12 hours and (see Table 7).
Table 7. Interferon, rabbit is to the lymphocytic regulating effect of T of PHA and ConA stimulation
| Tissue/the time | The LT CPM value of T | |||||
| The concentration of Interferon, rabbit (U/ml) | ||||||
| 0 (contrast) | 5 | 50 | 250 | 500 | 5000 | |
| Peripheral blood/12 hour (PHA group) | 773±88 | 769±96 | 823±79 | 812±58 | 1129±122 * | 532±44 * |
| Peripheral blood/24 hour (PHA group) | 786±79 | 779±92 | 771±64 | 804±96 | 1198±119 ** | 493±42 * |
| Peripheral blood/48 hour (PHA group) | 758±46 | 747±54 | 777±75 | 828±63 | 1245±101 ** | 428±62 * |
| Peripheral blood/12 hour (ConA group) | 610±51 | 573±31 | 678±56 | 976±84 ** | 1007±86 ** | 309±25 * |
| Peripheral blood/24 hour (ConA group) | 627±40 | 616±47 | 651±38 | 984±87 ** | 1021±104 ** | 271±31 ** |
| Peripheral blood/48 hour (ConA group) | 633±58 | 642±46 | 703±69 | 1016±104 ** | 1187±112 ** | 193±19 ** |
| Head-kidney/12 hour (PHA group) | 841±81 | 795±63 | 810±52 | 903±61 | 1365±114 * | 567±39 * |
| Head-kidney/24 hour (PHA group) | 830±74 | 862±61 | 906±92 | 970±101 | 1769±121 ** | 432±37 * |
| Head-kidney/48 hour (PHA group) | 854±52 | 847±64 | 876±71 | 1078±108 | 1842±134 ** | 445±22 * |
| Head-kidney/12 hour (ConA group) | 713±72 | 644±51 | 802±75 | 1002±91 | 1118±94 ** | 412±34 * |
| Head-kidney/24 hour (ConA group) | 691±22 | 709±32 | 792±41 | 1094±70 ** | 1376±142 ** | 387±22 * |
| Head-kidney/48 hour (ConA group) | 738±32 | 812±47 | 904±90 | 1138±122 ** | 1672±172 ** | 356±30 * |
*0.01＜P＜0.05,
*P＜0.01 t check (X ± SE, n=5)
5.4.2.2 Interferon, rabbit is to the regulating effect of mitogen LPS and SPA transformed B lymphocytes
Peripheral blood and head-kidney white corpuscle add final concentration respectively after Interferon, rabbit is handled be 125mg/ml LPS and 250mg/ml SPA, cultivates after 24 hours for 27 ℃ and carry out
3H-TdR mark (than degree 20Ci/mmol, concentration 1mCi/ml, mark final concentration 2 μ Ci/ml) labeled cell is used the per minute umber of pulse (CPM) of TRI-CARB 2050CA type liquid glimmer instrument working sample then.
The result shows that Interferon, rabbit is regulated the rule of SPA and LPS conversion peripheral blood and head-kidney bone-marrow-derived lymphocyte and regulate the T lymphocyte similar, also show as lower concentration and produce promoter action, and high density produces restraining effect.The dosage that produces promoter action is 50～500U/ml, and the time is more than the 12h, to be 5000U/ml and produce inhibiting dosage, and the time is (to see Table 8) more than 24 hours.
Table 8. Interferon, rabbit is to the regulating effect of the bone-marrow-derived lymphocyte conversion of LPS and SPA stimulation
| Tissue/the time | The CPM value that bone-marrow-derived lymphocyte transforms | |||||
| The concentration of Interferon, rabbit (U/ml) | ||||||
| 0 (contrast) | 5 | 50 | 250 | 500 | 5000 | |
| Peripheral blood/12 hour (SPA group) | 1393±93 | 1264±111 | 2879±226 ** | 2994±352 ** | 3042±194 ** | 879±56 |
| Peripheral blood/24 hour (SPA group) | 1407±56 | 1516±97 | 2911±321 ** | 3113±297 ** | 3199±301 ** | 142±37 ** |
| Peripheral blood/48 hour (SPA group) | 1464±61 | 1427±139 | 3004±317 ** | 3129±368 ** | 3244±281 ** | 119±24 ** |
| Peripheral blood/12 hour (LPS group) | 678±32 | 695±20 | 1925±68 ** | 1998±74 ** | 2071±101 ** | 492±79 |
| Peripheral blood/24 hour (LPS group) | 694±92 | 621±66 | 2014±101 ** | 2211±118 ** | 2364±191 ** | 104±29 ** |
| Peripheral blood/48 hour (LPS group) | 715±73 | 690±87 | 2116±117 ** | 2495±107 ** | 2731±201 ** | 111±37 ** |
| Head-kidney/12 hour (SPA group) | 893±76 | 839±52 | 2473±249 ** | 3871±378 ** | 2917±224 ** | 714±86 |
| Head-kidney/24 hour (SPA group) | 886±104 | 890±81 | 2511±301 ** | 3894±412 ** | 2881±301 ** | 206±21 |
| Head-kidney/48 hour (SPA group) | 897±96 | 878±112 | 2492±251 ** | 3997±501 ** | 2804±292 ** | 178±29 ** |
| Head-kidney/12 hour (LPS group) | 1142±57 | 1713±309 | 2178±213 ** | 4656±287 ** | 4682±301 ** | 1114±67 |
| Head-kidney/24 hour (LPS group) | 1194±69 | 1538±117 | 2634±311 ** | 4739±317 ** | 4699±268 ** | 317±32 ** |
| Head-kidney/48 hour (LPS group) | 1211±82 | 1734±201 | 2955±361 ** | 4834±412 ** | 4800±388 ** | 226±41 ** |
*0.01＜P＜0.05,
*P＜0.01 t check (X ± SE, n=5)
The fermentative production of the Yeast engineering bacteria of embodiment 6, expression GcIFN and the development of disease-resistant feed additive
Engineering bacteria carries out the small-scale fermentation with the 10L fermentor tank, and picking list bacterium colony seed engineering bacterium adds 200ml and contains in the SC-U substratum of 2% raffinose, and 30 ℃ of shaking culture are spent the night; Get culture and survey OD
600Value is calculated the culture amount of required inoculation in the 10L fermention medium, need reach 0.4 dosage by fermentation inducement substratum initial OD values, 4 ℃ of 1500g centrifugal collecting cells, after suspending with an amount of fermentation inducement substratum, inoculation is gone in the fermentor tank, 30 ℃ of fermentation culture 12～14 hours.Fermentation back yeast cell employing centrifuging (5000rpm, 20min) precipitation is collected, 15～25kHz ultrasonication, 25～30 ℃ of air stream dryings are made the yeast powder.Get an amount of bacterium powder, add the SDS-PAGE sample buffer, with the interferon protein in the SDS-PAGE electrophoretic method separated yeast bacterium powder, method is the same.With the relative expression quantity of tlc scanning determination Interferon, rabbit in yeast cell, the dosage that contains 10mg GcIFN by per kilogram fish (shrimp) artifical compound feed, add the Yeast engineering bacteria powder (expression amount of interferon protein in yeast generally can reach 30%, then adds 33mg yeast powder in per kilogram fish (shrimp) artifical compound feed) that contains GcIFN.
The disease-resistant test in aquaculture production of embodiment 7, GcIFN
1, to the disease-resistant test of cultured fishes
Test was carried out in 6～September; the net cage of culturing grass carp and perch is divided into 8 groups respectively; wherein 5 networking casees are test group; 3 groups is control group, and (the per kilogram feed adds the GcIFN engineering bacteria powder 33mg of preparation among the embodiment 5, the expression amount 30% of interferon protein in yeast to use the feed that contains Interferon, rabbit; the 10mgGcIFN/Kg feed) throws something and feeds; threw something and fed continuously for 4 weeks, statistics natural occurrence mortality ratio is calculated immune protective rate RPS.The result uses the experimental group that contains the Interferon, rabbit feed shown in table 9 and 10, surviving rate all obviously improves, and immune protective rate reaches 62.39% and 48.61% respectively, shows that IFN can obviously improve the immune disease-resistance ability of different fish.
Table 9 is cultured the disease-resistant test effect table of grass carp
| Group | Culture fate | Put number (tail) in a suitable place to breed | Death toll (tail) | Survival number (tail) | Surviving rate (%) | Average survival (%) | Surviving rate improves (%) | RPS (％) |
| Test 1 group | 90 | 1200 | 106 | 1094 | 91.16 | 92.36 | 12.67 | 62.39 |
| | 90 | 1200 | 58 | 1142 | 95.16 | |||
| Test 3 groups | 90 | 1200 | 126 | 1074 | 89.50 | |||
| Test 4 groups | 90 | 1000 | 78 | 922 | 92.20 | |||
| Test 5 groups | 90 | 900 | 56 | 844 | 93.78 | |||
| Contrast 1 group | 90 | 1200 | 225 | 975 | 81.25 | 79.69 | ||
| | 90 | 1200 | 248 | 952 | 79.33 | |||
| Contrast 3 groups | 90 | 1400 | 301 | 1099 | 78.50 |
Table 10 is cultured the disease-resistant test effect table of perch
| Group | Culture fate | Put number (tail) in a suitable place to breed | Death toll (tail) | Survival number (tail) | Surviving rate (%) | Average survival (%) | Surviving rate improves (%) | RPS (％) |
| Test 1 group | 90 | 1000 | 101 | 899 | 89.90 | 89.25 | 10.16 | 48.61 |
| | 90 | 1200 | 102 | 1098 | 91.50 |
| Test 3 groups | 90 | 1200 | 132 | 1068 | 89.00 | |||
| Test 4 groups | 90 | 800 | 92 | 708 | 88.50 | |||
| Test 5 groups | 90 | 800 | 101 | 699 | 87.37 | |||
| Contrast 1 group | 90 | 1200 | 220 | 980 | 81.66 | 79.08 | ||
| | 90 | 1200 | 264 | 936 | 78.00 | |||
| Contrast 3 groups | 90 | 1000 | 224 | 776 | 77.60 |
2, to the disease-resistant test of shrimps in culture
Test was carried out in 6～September.The net cage of culturing Penaeus vannamei and Chinese prawn is divided into 8 groups respectively; wherein 5 networking casees are test group; 3 groups is control group; use contains bait (the engineering bacteria powder 33mg of preparation among the per kilogram feed interpolation embodiment 5 of Interferon, rabbit; the expression amount 30% of interferon protein in yeast, the 10mgGcIFN/Kg feed) throw something and feed, threw something and fed continuously for 4 weeks; statistics natural occurrence mortality ratio is calculated immune protective rate RPS.The result uses the experimental group that contains the Interferon, rabbit feed shown in table 11 and 12, surviving rate all obviously improves, and immune protective rate reaches 30.80% and 20.99% respectively, shows that IFN can improve the immune disease-resistance ability of different shrimps.
Table 11 is cultured the disease-resistant test effect table of Penaeus vannamei
| Group | Culture fate | Put number (tail) in a suitable place to breed | Death toll (tail) | Survival number (tail) | Surviving rate (%) | Average survival (%) | Surviving rate improves (%) | RPS (％ ) |
| Test 1 group | 90 | 2000 | 454 | 1546 | 77.30 | 76.98 | 10.24 | 30.80 |
| | 90 | 2000 | 430 | 1570 | 78.50 | |||
| Test 3 groups | 90 | 1800 | 456 | 1344 | 74.66 | |||
| Test 4 groups | 90 | 2500 | 636 | 1864 | 74.56 | |||
| Test 5 groups | 90 | 2000 | 402 | 1598 | 79.90 | |||
| Contrast 1 group | 90 | 2000 | 650 | 1350 | 67.50 | 66.73 |
| | 90 | 2500 | 825 | 1675 | 67.00 | |||
| Contrast 3 groups | 90 | 2000 | 686 | 1314 | 65.70 |
Table 12 is cultured the disease-resistant test effect table of Chinese prawn
| Group | Culture fate | Put number (tail) in a suitable place to breed | Death toll (tail) | Survival number (tail) | Surviving rate (%) | Average survival (%) | Surviving rate improves (%) | RPS (％) |
| Test 1 group | 90 | 1500 | 512 | 988 | 65.86 | 65.38 | 9.20 | 20.99 |
| | 90 | 1500 | 556 | 944 | 62.93 | |||
| Test 3 groups | 90 | 1800 | 643 | 1157 | 64.27 | |||
| Test 4 groups | 90 | 1500 | 482 | 1018 | 67.86 | |||
| Test 5 groups | 90 | 1200 | 408 | 792 | 66.00 | |||
| Contrast 1 group | 90 | 1000 | 386 | 614 | 61.40 | 56.18 | ||
| | 90 | 1200 | 546 | 654 | 54.50 | |||
| Contrast 3 groups | 90 | 1200 | 568 | 632 | 52.66 |
At last, it is also to be noted that what more than enumerate only is several specific embodiments of the present invention.Obviously, the invention is not restricted to above embodiment, many distortion can also be arranged.All distortion that those of ordinary skill in the art can directly derive or associate from content disclosed by the invention all should be thought protection scope of the present invention.
Sequence table
SEQ ID NO.1
cagtgtagaa agctactact acctgaatac aaagatgaaa actcaaatgt ggacgtatat 60
gtttgtaatg tttttaactc tgcagggtca atgctctgct tgcgaatggc tcggccgata 120
caggatgata agcaacgagt ctttgagcct cctgaaggaa atgggtggaa aatatcctga 180
gggtaccaag gtgtcatttc caggacgcct gtacaacatg atagacaatg ccaaggtgga 240
ggaccaggtg aagtttcttg tcctgacctt agatcatatc atccgcctca tggatgccag 300
agagcacatg aattcagtgc agtggaacct acagactgta gagcattttc taactgtcct 360
gaacaggcag tcatctgatc ttaaagaatg tgtggcccga taccagccat cacataagga 420
gtcctacgag aaaaagataa acagacactt caagatttta aagaagaatc taaagaaaaa 480
agaatatagt gctcaagcat gggagcagat ccggagagct gtgaaacatc accttcagag 540
gatggacatc atcgcaagca ttgccaacag acgataagac ataatgacgg atgaatgact 600
tgtgacacat tccatggagt gaagaaaagt taatgtaaac aatgccttaa aagctaaaac 660
tgaatgtaac aaatatttat ttacatgact gtattttatt tcaactagag ttgaaagttt 720
tgcctaatgt ctggtgttgt aatatagagt ttaccttatg tgtttcctat gaaaacttga 780
agtaatctga tcaagcaagc taattatgtt tcttacaaaa acctgagaaa ccttgtattt 840
attttatttt ggtgcaaata ggcctatgtg cctaaactat acccagattt tttgctgaat 900
gtgaaaaaaa tgtttaaaaa aacaagcatg ccatgtattt caagtcatgt atttattaac 960
ggtcaatcaa ttatgttgtg atgcacatgg atatgatgta tgttttgtga ttgtttcaga 1020
tatttattat acttaattta cttcatacat tgttgtgcac aatttttgta tctctgaata 1080
ttttattctt tttatatgta ctgaatgctt gcgataatga tttgctctat ttgcttgcaa 1140
aatatttttg tacttttaaa taagaaattg attgaaaaaa aacaaaaaaa agtcgtgact 1200
gaaaaaacaa 1210
Claims (4)
1, a kind of recombinant plasmid that contains grass carp interferon gene, it is characterized in that: this gene has the nucleotide sequence shown in the SEQ IDNO.1.
2, a kind of engineering bacteria, it is characterized in that: this bacterial strain INVSC1-pYES2-IFN is S. cervisiae Saccharomyces cerevisiae, depositary institution: China Committee for Culture Collection of Microorganisms common micro-organisms center, preservation day: on October 19th, 2006, preserving number: CGMCC1847.
3, the application of engineering bacteria as claimed in claim 2 in aquatic animal is antiviral.
4, the application of a kind of protein in aquatic animal is antiviral is characterized in that: this protein is that to have a grass carp interferon gene of nucleotide sequence shown in the SEQ ID NO.1 coded.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610155119A CN100577806C (en) | 2006-12-08 | 2006-12-08 | Recombinant plasmid and engineering bacterium containing grass carp interferon gene and their application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610155119A CN100577806C (en) | 2006-12-08 | 2006-12-08 | Recombinant plasmid and engineering bacterium containing grass carp interferon gene and their application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1974775A true CN1974775A (en) | 2007-06-06 |
| CN100577806C CN100577806C (en) | 2010-01-06 |
Family
ID=38125122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610155119A Expired - Fee Related CN100577806C (en) | 2006-12-08 | 2006-12-08 | Recombinant plasmid and engineering bacterium containing grass carp interferon gene and their application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100577806C (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102021175A (en) * | 2010-11-18 | 2011-04-20 | 中国科学院微生物研究所 | Optimized grass carp alpha interferon encoding gene and application thereof |
| CN102747086A (en) * | 2011-04-18 | 2012-10-24 | 电子科技大学 | Gene and protein of grass carp interleukin 10 and recombinant expression method thereof |
| CN104043111A (en) * | 2014-06-25 | 2014-09-17 | 中国水产科学研究院黑龙江水产研究所 | Application of rainbow trout IFN-gamma2 (Interferon-gamma2) in preparing anti-IHN (Infectious Haematopoietic Necrosis) virus product |
| CN104686845A (en) * | 2015-03-10 | 2015-06-10 | 浙江皇冠科技有限公司 | Nature feed additive for microorganism-derived aquatic animals, and application of nature feed additive |
| CN105200082A (en) * | 2015-08-18 | 2015-12-30 | 浙江省淡水水产研究所 | Eukaryotic expression plasmid pEGFP-IFNalpha wrapped with lipidosome and application |
| CN105331570A (en) * | 2015-11-30 | 2016-02-17 | 中国科学院水生生物研究所 | Blue alga engineering bacterium containing crucian IFN interferon and application |
| CN108379559A (en) * | 2018-05-23 | 2018-08-10 | 华中农业大学 | Application of the grass carp interferon 1 in preparing antibacterials |
| CN108998384A (en) * | 2018-06-25 | 2018-12-14 | 浙江皇冠科技有限公司 | Recombinate the engineering bacteria of fish interferon and its preparation method of product |
| CN110628818A (en) * | 2019-09-25 | 2019-12-31 | 中国科学院水生生物研究所 | Preparation method and application of fish skin mucous gland bioreactor |
| CN114891087A (en) * | 2022-04-26 | 2022-08-12 | 浙江皇冠科技有限公司 | Grass carp interferon, grass carp interferon mutant and application and product thereof |
-
2006
- 2006-12-08 CN CN200610155119A patent/CN100577806C/en not_active Expired - Fee Related
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102021175A (en) * | 2010-11-18 | 2011-04-20 | 中国科学院微生物研究所 | Optimized grass carp alpha interferon encoding gene and application thereof |
| CN102021175B (en) * | 2010-11-18 | 2012-12-19 | 中国科学院微生物研究所 | Optimized grass carp alpha interferon encoding gene and application thereof |
| CN102747086A (en) * | 2011-04-18 | 2012-10-24 | 电子科技大学 | Gene and protein of grass carp interleukin 10 and recombinant expression method thereof |
| CN104043111A (en) * | 2014-06-25 | 2014-09-17 | 中国水产科学研究院黑龙江水产研究所 | Application of rainbow trout IFN-gamma2 (Interferon-gamma2) in preparing anti-IHN (Infectious Haematopoietic Necrosis) virus product |
| CN104043111B (en) * | 2014-06-25 | 2015-12-30 | 中国水产科学研究院黑龙江水产研究所 | The application of rainbow trout IFN-γ 2 in the anti-IHN viral product of preparation |
| CN104686845A (en) * | 2015-03-10 | 2015-06-10 | 浙江皇冠科技有限公司 | Nature feed additive for microorganism-derived aquatic animals, and application of nature feed additive |
| CN105200082A (en) * | 2015-08-18 | 2015-12-30 | 浙江省淡水水产研究所 | Eukaryotic expression plasmid pEGFP-IFNalpha wrapped with lipidosome and application |
| CN105331570A (en) * | 2015-11-30 | 2016-02-17 | 中国科学院水生生物研究所 | Blue alga engineering bacterium containing crucian IFN interferon and application |
| CN105331570B (en) * | 2015-11-30 | 2019-04-02 | 中国科学院水生生物研究所 | A kind of algae engineering bacteria containing crucian IFN interferon and application |
| CN108379559A (en) * | 2018-05-23 | 2018-08-10 | 华中农业大学 | Application of the grass carp interferon 1 in preparing antibacterials |
| CN108998384A (en) * | 2018-06-25 | 2018-12-14 | 浙江皇冠科技有限公司 | Recombinate the engineering bacteria of fish interferon and its preparation method of product |
| CN110628818A (en) * | 2019-09-25 | 2019-12-31 | 中国科学院水生生物研究所 | Preparation method and application of fish skin mucous gland bioreactor |
| CN110628818B (en) * | 2019-09-25 | 2023-04-11 | 中国科学院水生生物研究所 | Preparation method and application of fish skin mucous gland bioreactor |
| CN114891087A (en) * | 2022-04-26 | 2022-08-12 | 浙江皇冠科技有限公司 | Grass carp interferon, grass carp interferon mutant and application and product thereof |
| CN114891087B (en) * | 2022-04-26 | 2023-08-11 | 浙江皇冠科技有限公司 | Grass carp interferon, grass carp interferon mutant, application and product thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100577806C (en) | 2010-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100577806C (en) | Recombinant plasmid and engineering bacterium containing grass carp interferon gene and their application | |
| CN106540240B (en) | Preparation and application of antibacterial peptide fusion cell factor CAMPILs co-expression biological agent | |
| CN101054584A (en) | Fish interferon gene and use thereof | |
| CN101182360B (en) | Fusion protein having antibiotic function and uses thereof | |
| CN103865933B (en) | The application of a kind of WAP gene in Drosophila transgenic | |
| CN1970772A (en) | Sequence, plasmid, and engineering bacteria for use in disease control of aquatic animal and application thereof | |
| CN1313763A (en) | Natural physiologically active substances efficacious against fish diseases and fish feeds containing the same | |
| WO2018186522A1 (en) | Vaccine composition comprising vhsv vaccine and adjuvant | |
| CN102899331B (en) | Complex duck interferon-alpha gene, and recombinant vector and application thereof | |
| CN1583792A (en) | Vitellus immune globulin for preventing prawn virus, tis preparing method and use thereof | |
| CN103074362B (en) | Production process and application of antibacterial peptide used in animal feed | |
| CN115068600A (en) | Application of antiviral protein immunopotentiator in H9N2 avian influenza inactivated vaccine | |
| CN104521828A (en) | Method for building gyrodactylus purebred artificial infection system | |
| CN102091089A (en) | Application of active burdock oligosaccharide to aquaculture | |
| CN1467291A (en) | Avian interleukin-2 (IL-2) gene and eukaryon expressing plasmid and immunity reinforcing agent of bird vaccine | |
| CN1277925C (en) | Recombinant Baculovirus for expressing CTB and human insulin fusion protein and use thereof | |
| CN106232133A (en) | Purposes with the immune stimulator of starch associated proteins (SBP) label | |
| TWI540968B (en) | Method for lowering feed conversion rate | |
| CN107261113B (en) | Application of natural host defense peptide Alligatorin5 | |
| CN108129570A (en) | Merge the preparation and application of ox antibacterial peptide and interleukin 2 coexpression recombination yeast bacteria preparation | |
| CN108998384A (en) | Recombinate the engineering bacteria of fish interferon and its preparation method of product | |
| Kim et al. | Immersion bath treatment of tilapia fry with myostatin-1 prodomain does not affect tilapia growth at market size | |
| CN1308124A (en) | Preparation and application of antibiotic peptide beer yeast | |
| CN1889976A (en) | Pharmaceutical anti-herpetic composition, method for producing a dosage form based thereon and method for the use thereof | |
| Nuryati et al. | Maternal Immunity and Immune Improvement of Koi Cyprinus rubrofuscus Larvae after DNA Vaccine against Hoi Herpesvirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100106 Termination date: 20101208 |